| Heterogeneity of genomic evolution and mutational profiles in multiple myeloma N Bolli, H Avet-Loiseau, DC Wedge, P Van Loo, LB Alexandrov, ... Nature communications 5 (1), 2997, 2014 | 953 | 2014 |
| Telomeres, lifestyle, cancer, and aging MA Shammas Current Opinion in Clinical Nutrition & Metabolic Care 14 (1), 28-34, 2011 | 835 | 2011 |
| Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis FE Davies, AM Dring, C Li, AC Rawstron, MA Shammas, SM O'Connor, ... Blood 102 (13), 4504-4511, 2003 | 307 | 2003 |
| Dysfunctional T regulatory cells in multiple myeloma RH Prabhala, P Neri, JE Bae, P Tassone, MA Shammas, CK Allam, ... Blood 107 (1), 301-304, 2006 | 290 | 2006 |
| Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 256 | 2012 |
| Telomerase inhibition by peptide nucleic acids reversesimmortality'of transformed human cells MA Shammas, CG Simmons, DR Corey, RJ Shmookler Reis Oncogene 18 (46), 6191-6200, 1999 | 213 | 1999 |
| Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications MA Shammas, P Neri, H Koley, RB Batchu, RC Bertheau, V Munshi, ... Blood 108 (8), 2804-2810, 2006 | 200 | 2006 |
| Genomic patterns of progression in smoldering multiple myeloma N Bolli, F Maura, S Minvielle, D Gloznik, R Szalat, A Fullam, ... Nature communications 9 (1), 3363, 2018 | 187 | 2018 |
| Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells P Tassone, VS Goldmacher, P Neri, A Gozzini, MA Shammas, ... Blood 104 (12), 3688-3696, 2004 | 182 | 2004 |
| In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56 … P Tassone, A Gozzini, V Goldmacher, MA Shammas, KR Whiteman, ... Cancer research 64 (13), 4629-4636, 2004 | 175 | 2004 |
| Identification of genes modulated in multiple myeloma using genetically identical twin samples NC Munshi, T Hideshima, D Carrasco, M Shammas, D Auclair, F Davies, ... Blood 103 (5), 1799-1806, 2004 | 174 | 2004 |
| Elevated Recombination in Immortal Human Cells Is Mediated by HsRAD51 Recombinase SJ Xia, MA Shammas, RJ Shmookler Reis Molecular and cellular biology 17 (12), 7151-7158, 1997 | 171 | 1997 |
| A clinically relevant SCID-hu in vivo model of human multiple myeloma P Tassone, P Neri, DR Carrasco, R Burger, VS Goldmacher, R Fram, ... Blood 106 (2), 713-716, 2005 | 163 | 2005 |
| Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma MA Shammas, RJS Reis, C Li, H Koley, LH Hurley, KC Anderson, ... Clinical Cancer Research 10 (2), 770-776, 2004 | 158 | 2004 |
| Dysfunctional homologous recombination mediates genomic instability and progression in myeloma MA Shammas, RJ Shmookler Reis, H Koley, RB Batchu, C Li, NC Munshi Blood, The Journal of the American Society of Hematology 113 (10), 2290-2297, 2009 | 144 | 2009 |
| Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential MA Shammas, H Koley, RB Batchu, RC Bertheau, A Protopopov, ... Molecular Cancer 4, 1-14, 2005 | 139 | 2005 |
| Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo MA Shammas, H Koley, RC Bertheau, P Neri, M Fulciniti, P Tassone, ... Leukemia 22 (7), 1410-1418, 2008 | 125 | 2008 |
| Effects of oligonucleotide N3'→ P5'thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells M Akiyama, T Hideshima, MA Shammas, T Hayashi, M Hamasaki, YT Tai, ... Cancer research 63 (19), 6187-6194, 2003 | 118 | 2003 |
| Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma MA Shammas, RJ Shmookler Reis, M Akiyama, H Koley, D Chauhan, ... Molecular cancer therapeutics 2 (9), 825-833, 2003 | 112 | 2003 |
| Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of … P Tassone, P Neri, R Burger, R Savino, M Shammas, L Catley, K Podar, ... Clinical cancer research 11 (11), 4251-4258, 2005 | 109 | 2005 |
